tbuckley/cabot-search huggingface dataset:
Impact of telemedicine on colonoscopy education among veterans.
Authors: Thi Khuc, Christian Jackson, Daniel Chao
Journal: Journal of Clinical Oncology (2019)

276 Background: The VA Loma Linda Healthcare System (LLVA) offers an in-person colonoscopy education class (IPCC) and a telehealth based education class to patients living closer to outlying VA designated Community Based Outpatient Clinics (CBOCs). We noticed a significant number of cancellations and no-shows for colonoscopy from patients who sought care from CBOCS. We developed a telehealth based colonoscopy class (TBCC) to be given at CBOCs. The primary aim of the study was to determine effectiveness of TBCC compared to IPCC on class attendance rates, colonoscopy attendance and quality measures of colonoscopy. Methods: We reviewed records of 1429 LLVA and CBOC patients referred for colonoscopy class from April 2014 to April 2015. Primary end points were polyp detection rate (PDR), adenomas detection rate (ADR) and adenocarcinoma detection rate (ACDR). Secondary endpoints were attendance to TBCC and IPCC and attendance to colonoscopy. Attendance was defined as compliance with the first scheduled appointment. We examined age, BMI, sex, race, and indication for colonoscopy in the IPCC and TBCC populations. Results: TBCC attendance rate was higher than IPCC (p = 0.001). There was no difference in attendance to colonoscopy (p = 0.50). Patients receiving primary care at CBOCs more likely chose TBCC; patients receiving primary care at LLVA more likely chose IPCC (92.53% vs 24.77%, p &lt; 0.0001). African Americans and Hispanics more likely chose IPCC; Whites more likely chose TBCC (p = .01). Patients with family history of colorectal cancer or bright red blood per rectum more likely chose IPCC (p = 0.004, p = 0.008). Sixty eight percent of colonoscopy preparations were noted to be good. There was no difference in the number of good preparations between TBCC and IPCC groups (94.3% and 96%, p = 0.025). ADR was higher in patients who received IPCC (44.55% and 52.17%, p = 0.02). There was no significant difference in PDR and ACDR between TBCC and IPCC groups. Conclusions: A TBCC program can increase patient attendance to colonoscopy preparation training without negatively affecting quality of colonoscopy preparation. Prospective, randomized studies on differences in adenoma detection and distance from home residence on class and colonoscopy attendance rates is needed.
XPO1 Inhibition Disrupts Ribosomal Subunits Assembly and Induces Multiple Myeloma (MM) Cell Death
Authors: Ines Tagoug, Paola Neri, Jiri Slaby, Jacquelyn Babich, Justin Simms, Kathy Gratton, Li Ren, Nizar J. Bahlis
Journal: Blood (2013)
Engineered antibody-functionalized porous silicon nanoparticles for therapeutic targeting of pro-survival pathway in endogenous neuroblasts after stroke
Authors: Vimalkumar Balasubramanian, Andrii Domanskyi, Juho-Matti Renko, Mirkka Sarparanta, Chang-Fang Wang, Alexandra Correia, Ermei Mäkilä, Osku S. Alanen, Jarno Salonen, Anu J. Airaksinen, Raimo Tuominen, Jouni Hirvonen, Mikko Airavaara, Hélder A. Santos
Journal: Biomaterials (2019)

Generation of new neurons by utilizing the regenerative potential of adult neural stem cells (NSCs) and neuroblasts is an emerging therapeutic strategy to treat various neurodegenerative diseases, including neuronal loss after stroke. Committed to neuronal lineages, neuroblasts are differentiated from NSCs and have a lower proliferation rate. In stroke the proliferation of the neuroblasts in the neurogenic areas is increased, but the limiting factor for regeneration is the poor survival of migrating neuroblasts. Survival of neuroblasts can be promoted by small molecules; however, new drug delivery methods are needed to specifically target these cells. Herein, to achieve specific targeting, we have engineered biofunctionalized porous silicon nanoparticles (PSi NPs) conjugated with a specific antibody against polysialylated neural cell adhesion molecule (PSA-NCAM). The PSi NPs loaded with a small molecule drug, SC-79, were able to increase the activity of the Akt signaling pathway in doublecortin positive neuroblasts both in cultured cells and in vivo in the rat brain. This study opens up new possibilities to target drug effects to migrating neuroblasts and facilitate differentiation, maturation and survival of developing neurons. The conjugated PSi NPs are a novel tool for future studies to develop new therapeutic strategies aiming at regenerating functional neurocircuitry after stoke.
Glycosaminoglycan-based biomaterials for growth factor and cytokine delivery: Making the right choices
Authors: Daniel Hachim, Thomas E. Whittaker, Hyemin Kim, Molly M. Stevens
Journal: Journal of Controlled Release (2019)

Controlled, localized drug delivery is a long-standing goal of medical research, realization of which could reduce the harmful side-effects of drugs and allow more effective treatment of wounds, cancers, organ damage and other diseases. This is particularly the case for protein "drugs" and other therapeutic biological cargoes, which can be challenging to deliver effectively by conventional systemic administration. However, developing biocompatible materials that can sequester large quantities of protein and release them in a sustained and controlled manner has proven challenging. Glycosaminoglycans (GAGs) represent a promising class of bio-derived materials that possess these key properties and can additionally potentially enhance the biological effects of the delivered protein. They are a diverse group of linear polysaccharides with varied functionalities and suitabilities for different cargoes. However, most investigations so far have focused on a relatively small subset of GAGs - particularly heparin, a readily available, promiscuously-binding GAG. There is emerging evidence that for many applications other GAGs are in fact more suitable for regulated and sustained delivery. In this review, we aim to illuminate the beneficial properties of various GAGs with reference to specific protein cargoes, and to provide guidelines for informed choice of GAGs for therapeutic applications.
Evaluation of scheduled video visits for cancer care at the Sidney Kimmel Cancer Center at Thomas Jefferson University.
Authors: Nathan Handley, Adam Binder, Megan Sabonjian, Ana Maria Lopez
Journal: Journal of Clinical Oncology (2019)

277 Background: Telehealth is currently undergoing exponential growth as a result of improved access through less costly, more portable, and better quality technology and through increased broadband internet proliferation. Telehealth has been shown to improve access and decrease costs while maintaining quality of care and high levels of patient satisfaction. One approach to telehealth is the video visit, in which audiovisual technology is used to connect patients and providers virtually. We implemented a pilot scheduled video visit program in a large academic cancer center (SKCC). Methods: Oncology clinical teams were trained in the use of JeffConnect, the video visit platform developed at our institution. Clinical teams were encouraged to utilize video visits in instances they deemed appropriate (i.e. post hospital follow-up, post-chemotherapy evaluations). All participating patients received a link to an evaluation following completion of the video visit. A subset of patients receiving more detailed survey questions. We reviewed evaluations occurring between 9/1/2016 and 3/31/2019. Results: Sixty-nine unique clinicians and 759 unique patients engaged in 865 completed telemedicine visits. For these, 118 surveys were completed and returned (14.03% of total visits), a similar response rate for other services. Average likelihood to recommend JeffConnect to a friend or colleague was 9.1 (scale 0-10). The majority of patients reported video visits saved them time (Figure 1) and money. For the subset of patients receiving the more detailed survey (n=30), average distance from SKCC at the time of the visit was 125 miles (range 10-963 miles, median 50) and average financial savings were $61.15 (range $8-$300, median $45). Conclusions: Scheduled cancer care video visits were feasible, resulted in high patient satisfaction, and saved patients time and money. Evaluating patient and clinician perceptions of the benefits of and barriers to telemedicine in greater detail is necessary for broader implementation. Patient-reported time saved by telemedicine. [Table: see text]
Abstract 297: Therapeutic Effects of SK Channel Activator on Cardioprotection in the Setting of Cardioplegic Ischemia-Reperfusion and Cardiopulmonary Bypass
Authors: Zhiqi Zhang, Neel R Sodha, Vasile Pavlov, Ahmad Aboulgheit, Richard Clements, Martin A Kolodziejczak, Frank W Sellke, Jun Feng
Journal: Circulation Research (2019)

Background: Inactivation of small-conductance calcium-activated potassium (SK) channels contributes to coronary microvascular dysfunction in patients after cardioplegic arrest, cardiopulmonary bypass (CP/CPB) and cardiac surgery. SK-channel activation is cardioprotective in rodent isolated heart model of myocardial infarction and ischemia/reperfusion. In the current study, we investigated the impact of SK activation on myocardial protection in a clinically relevant large animal model of pigs subjected to cardioplegic ischemia/reperfusion and CPB. Methods and Results: Ten Yorkshire pigs were subjected to 1 hour of CP/CPB followed by 1 hour of reperfusion. Pigs received either cold blood hyperkalemic CP alone (CP control) or CP containing the selective SK channel activator NS309 (10 -6 M, n = 5/group). Left ventricular (LV) function was assessed by using pressure-volume loop analysis. Coronary arteriolar relaxation response (in-vitro) to the endothelium-dependent vasodilators adenosine diphosphate (ADP, 10 -9 -10 -4 M) and substance P (10 -12 -10 -7 M) and independent vasodilator sodium nitroprusside (SNP) was evaluated with video-microscopy. Inclusion of NS309 in cold blood CP tends to improve the recovery of LV function compared with the CP controls. CP/CPB and reperfusion significantly reduced endothelium-dependent relaxation response to ADP, 10 -5 M) and substance P (10 -8 M) as compared to control (p&lt;0.05). In contrast, CP-containing NS309 significant improved the recovery of endothelium-dependent relaxation response to ADP and substance P as compared with the control group (p&lt;0.05, respectively). Conclusion: In pig model of CP/CPB, inclusion of the selective SK channel activator in the cold blood cardioplegia improves recovery of coronary arteriolar endothelial function and microvascular relaxation, which may contribute to increased myocardial perfusion and improved LV function.
Recombinant Human Thrombopoietin Increases Platelet Numbers and Reduces the Risk of Bleeding Events in Thrombocytopenic Patients with Chronic Hepatitis B Virus Infection: A Multicenter Observational Study
Authors: Wan-Yi Zhai, Ru Feng, Xiao-Lu Zhu, Yun He, Hai-Xia Fu, Yi Liu, Jian-Liang Shen, Qian Jiang, Hao Jiang, Jin Lu, Qian-Ming Wang, Jing-Wen Wang, Hui Liu, Hao Wang, Hui Ma, Yan-Di Xie, Lan-Ping Xu, Kai-Yan Liu, Xiao-Jun Huang, Xiaohui Zhang
Journal: Blood (2018)
Diffuse Hyperpigmentation in Infants During Monsoon Season
Authors: Garima Dabas, Keshavamurthy Vinay, Rahul Mahajan
Journal: JAMA Dermatology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Understanding palbociclib practice patterns in a real-world setting.
Authors: Gabrielle Betty Rocque, Joanne Lorraine Blum, Aldemar Montero, Sharon Wilks, Daniel M. Anderson, Mohamad Adham Salkeni, Sami Diab, John J. Migas, Ibrahim Nakhoul, Derrick W. Spell, Bethany G. Sleckman, Joseph C Cappelleri, Yao Wang, Debu Tripathy
Journal: Journal of Clinical Oncology (2019)

200 Background: Real-world practice patterns often differ from treatment in clinical trials. We assessed real-world standard-of-care treatment with palbociclib (PAL) in the context of previously reported PALOMA trial results. Methods: POLARIS is a prospective, observational study of PAL in patients (pts) with hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer. Baseline demographics, clinical characteristics, initial treatment dose, dose modifications, dose delays, and adverse events (AEs) during the first 6 months (mo) of treatment were analyzed. Results: 412 pts enrolled at 92 US sites had at least 6 mo of PAL treatment; 73% received PAL in the first-line setting and 27% in second or later line. While a majority of pts received the recommended dose of 125 mg/d; 6% and 1% started at 100 mg and 75 mg, respectively. Physician-reported reasons for choosing a lower dose were: comorbidities (31%), pt age (21%), past treatment (10%), patient preference (3%), and other (34%). Selected pt and clinical characteristics, dosing, and treatment outcomes in POLARIS and in PALOMA-2 are shown in Table. Conclusions: In a real-world data set of 6 mo of PAL treatment, most pts started at the recommended dose, with tolerability and safety outcomes consistent with those reported in clinical trials. Differing populations, treatment patterns, and outcome reporting in real world vs trial settings underscore the need to study real-world practices and outcomes. Clinical trial information: NCT03280303 [Table: see text]
Navigating costs of care in women with breast cancer: Examining racial differences in non-treatment costs and financial toxicity in under-resourced populations struggling to afford medical care.
Authors: Kathleen D. Gallagher, Brittnee Barris, Eric Anderson, Katie Deehr, Shonta Chambers, Courtney Williams, Gabrielle Betty Rocque, Alan James Balch
Journal: Journal of Clinical Oncology (2019)

156 Background: Patients with cancer struggle to afford needed medical care alongside daily financial obligations due to rising healthcare costs. This may be more pronounced among minorities who are less likely to seek resources to mitigate their financial distress. This study sought to identify racial differences in non-treatment costs for under-resourced women with breast cancer who sought assistance from Patient Advocate Foundation (PAF). Methods: This cross-sectional study utilized secondary survey data collected from breast cancer patients receiving case management services from PAF in 2018. Respondents answered questions describing their financial distress and COmprehensive Score for financial Toxicity (COST) tool (0-44 with lower scores indicating worse toxicity). Descriptive statistics were calculated using means and standard deviations (SD) for continuous variables and frequencies for categorical variables. Two sample t-tests were used for bivariate comparisons between racial groups. Results: Of 267 breast cancer patients surveyed, 54% were Caucasian, 29% were African American (AA), and 83% indicated a household income of &lt; $48,000. Cohorts expressed strong dissatisfaction with their financial situation with AA impacted more acutely (78% vs 56%) and acknowledged inability to pay for treatment costs (83% vs 58%). Compared to Caucasians, AAs were more often concerned with transportation costs (33% vs 16%) and with day-to-day living expenses (83% vs 59%). Younger (≤55 years) AA respondents were twice as often unable to meet monthly expenses (60% vs. 27%). Older AA respondents ( &gt; 55 years) reported greater distress than older Caucasians (74% vs 57%), while younger Caucasians reported greater distress than their AA counterparts (72% vs 65%). COST scores differed significantly between Caucasians (mean 13, SD 9) and AAs (mean 11, SD 8; p = 0.04). Conclusions: While the impacts of medical care costs were felt by all survey respondents, under-resourced AA breast cancer patients may be at higher risk for household material hardships as financial resources are diverted toward essential healthcare costs.
Abstract 730: Celltype-Specific Functions in Dilated Cardiomyopathy Caused by the <i>LMNA</i> Gene Mutation
Authors: Kunal Sikder, Elizabeth Phillips, Zhijiu Zhong, Nadan Wang, Kenneth B Margulies, Jason C Choi
Journal: Circulation Research (2019)

Mutations in the LMNA gene, encoding lamins A and C (lamin A/C) cause a diverse group of human diseases termed laminopathies. The most prevalent laminopathy is dilated cardiomyopathy (herein referred to as LMNA cardiomyopathy) characterized by variable onset of fibrosis/pathological remodeling that always progresses to heart failure. Despite recent progress, how cell type-specific effects of LMNA mutations are integrated at the tissue level to engender complex pathologies in a heterocellular organ such as the heart are not well understood. Using a conditional deletion model that permits cardiomyocyte (CM)-specific Lmna deletion coupled with translating ribosome affinity purification, we found that CM-specific lamin A/C depletion caused rapid fibrosis and severe cardiac dysfunction accompanied by endoplasmic reticulum (ER) stress. At the molecular level, CM-specific translating mRNA profiling identified increased expression of MED25, a member of the Mediator complex implicated in regulating ER stress responses, prior to the onset of cardiac dysfunction. In contrast, lamin A/C depletion selectively in cardiac fibroblasts (CFs) displayed no immediate cardiac pathology whereas a concurrent depletion in both CMs and CFs resulted in lesser fibrosis and pathological remodeling. These results suggest that lamin A/C play an important role in CF biology and that reactive CFs underlie the rapid onset and the exaggerated LMNA cardiomyopathy symptoms observed in mice with CM-only Lmna deletion. Mechanistically, we found that increased matrix stiffness elevated the expression of MED25 and ER stress markers in lamin A/C-depleted CMs in vitro , indicating that the physical component of fibrosis may underlie the observed molecular changes. Taken together, our results suggest lamin A/C-depleted CFs mediate a brake on cardiomyopathy development and interactions between CFs and CMs are important determinants of the rate of progression and the severity of LMNA cardiomyopathy. Therefore, strategies targeting lamin A/C function in CFs may hold therapeutic potential for patients with LMNA cardiomyopathy as well as for other forms of cardiomyopathy in which fibrosis is integral to disease pathogenesis.
Without GABP Transcription Factor, BCR-ABL Cannot Transform HSCs to Leukemic Stem Cells Nor Induce Chronic Myelogenous Leukemia in Mice
Authors: Zhongfa Yang, Cong Peng, Yaoyu Chen, Junling Wang, Xuejun Zhu, Karen Drumea, Shaoguang Li, Alan G. Rosmarin
Journal: Blood (2011)
Abstract 646: Myocardial Ischemia/Reperfusion Impairs Adipocyte Endocrine Function via Exosome-Mediated Endoplasmic Reticulum Dysfunction
Authors: Lu Gan, Dina Xie, Wayne Lau, Theodore Christopher, Bernard Lopez, Ling Zhang, Jing Liu, Erhe Gao, Walter Koch, Yajing Wang, Xinliang Ma
Journal: Circulation Research (2019)

By incompletely understood mechanisms, MI patients sustain systemic metabolic disorder. Adipocytes are an important cellular type regulating energy homeostasis. The impact of MI upon adipocyte function remains unknown. Exosomes (Exo) are critical vehicles mediating organ-organ communication. However, whether and how Exo may mediate post-MI cardiomyocyte/adipocyte communication have not been previously investigated. Adult male mice were subjected to MI/R. Serum Exo were isolated 3 hours after R and incubated with 3T3L cells for 24 hours. Compared to control, MI/R Exo significantly altered the expression of 17 genes known to be important in adipocyte function. GO analysis revealed that genes associated with endoplasmic reticulum (ER) function and adipocyte endocrine function are the primary two pathways altered by MI/R Exo. Venn analysis identified 11 mi-RNAs as cardiac-enriched, adipocyte-poor, and ER function-related miRNAs. RT-qPCR confirmed the miR-23a/27a/24-2 family members are the most markedly increased mi-RNAs in MI/R Exo. Incubation of 3T3L cells with mi-R27a mimic significantly downregulated EDEM3, DsBA-L, and PPARγ, and upregulated PERK and CHOP. Conversely, mi-R27a inhibitor significantly decreased the impact of MI/R Exo upon ER function genes. Additional studies demonstrated EDEM3 and PPARγ (two critical molecules maintaining ER function and adipocyte endocrine function) to be direct targets of mi-R27a. One of the most significant endocrine molecules of adipocyte origin, adiponectin is regulated by PPARγ at the transcriptional level and by DsBA-L at the post-translational level. We next determined whether MI/R Exo may affect adiponectin expression/assembly. Incubation of 3T3L cells with MI/R Exo significantly inhibited total and high molecular weight adiponectin expression, an effect blocked by miR27a mimic. Finally, in vivo administration of GW4869 (Exo biogenesis inhibitor) or miR27a inhibitor attenuated adipocyte ER dysfunction and restored plasma adiponectin level in MI/R animals. We demonstrate for the first time that MI/R causes significant adipocyte ER and endocrine dysfunction by Exo mediated cardiomyocyte/adipocyte communication via miR-23a/27a/24-2.
B Cell Receptor-ERK1/2 Signal Cancels PAX5-Dependent Repression of BLIMP1 Probably Through PAX5 Phosphorylation: A Mechanism of Antigen-Triggering Plasma Cell Differentiation
Authors: Takahiko Yasuda, Fumihiko Hayakawa, Shingo Kurahashi, Tomoki Naoe
Journal: Blood (2011)